Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Chanson, P.    Harris, A. G.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 Patients

Philippe Chanson; Bruce D. Weintraub; and Alan G. Harris

1 August 1993 | Volume 119 Issue 3 | Pages 236-240

Objective: To evaluate the efficacy of octreotide in the treatment of pituitary thyroid-stimulating hormone (TSH)-secreting adenomas.

Data Sources: Combination of review and original data. Review data included information supplied by Sandoz Pharmaceuticals from patient case report forms and information from abstracts and articles published in the French or English language between 1987 and 1991. Original data included follow-up data on 15 of 37 previously reported cases and data on 15 new cases provided by 11 investigators.

Study Selection: Fifty-two cases from 24 medical centers in nine countries reported between 1987 and 1991.

Data Extraction: Chief clinical characteristics of the patients; dose and duration of octreotide treatment; serum TSH, thyroid hormone, and free -subunit levels before and during treatment; serial anatomic evaluation of the pituitary gland by either computed tomographic scanning or magnetic resonance imaging; and side effects.

Data Synthesis: After the first octreotide dose (50 to 100 µg), TSH levels decreased in all but 2 patients (mean decrease for the whole group, 55.8% ± 27%). Levels of -subunit decreased in 15 of the 19 patients who had -subunit assessments (mean decrease, 37.5% ± 24%). Reduction of TSH levels after short-term treatment (50 or 100 µg two or three times daily) was observed in 30 of 33 patients (mean decrease, 74.1%). Thyroid hormone levels were reduced in all patients and returned to normal in 73%. Despite an initial response to therapy, thyroid hormone levels continued to rise ("true escape") in 2 patients receiving short-term therapy and in 3 patients receiving long-term therapy. Partial shrinkage of the adenoma occurred in 11 patients.

Conclusions: Octreotide is an effective treatment for TSH-secreting adenomas. Thyroid-stimulating hormone levels almost always decreased, and thyroid hormone levels reverted to normal in about three quarters of patients. Partial tumor shrinkage was observed in one third of patients receiving long-term octreotide treatment.

Author and Article Information

From Hopital Lariboisiere, Paris, France; National Institutes of Health, Bethesda, Maryland; Cedars-Sinai Medical Center, Los Angeles, California.
Requests for Reprints: Philippe Chanson, MD, Department of Internal Medicine and Endocrinology, Hopital Lariboisiere, 2 rue Ambroise Pare, F 75475 Paris Cedex 10, France.
Acknowledgments: The authors thank Dr. A. Warnet for his support during the study; the investigators who provided data on their patients; Mrs. C. Seiler for help in the literature search; and Mrs. P. Tomi for secretarial assistance.

This article has been cited by other articles:

				C. Lu, M. C. Willingham, F. Furuya, and S.-y. Cheng Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary Tumors Endocrinology, July 1, 2008; 149(7): 3339 - 3345. [Abstract] [Full Text] [PDF]

				T. Kienitz, M. Quinkler, C. J Strasburger, and M. Ventz Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature Eur. J. Endocrinol., July 1, 2007; 157(1): 39 - 46. [Abstract] [Full Text] [PDF]

				J. van der Hoek, S. W J Lamberts, and L. J Hofland Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S45 - S51. [Abstract] [Full Text] [PDF]

				C Daousi, P M Foy, and I A MacFarlane Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 93 - 95. [Abstract] [Full Text] [PDF]

				W. W. Woodmansee, J. M. Kerr, E. A. Tucker, J. R. Mitchell, D. J. Haakinson, D. F. Gordon, E. C. Ridgway, and W. M. Wood The Proliferative Status of Thyrotropes Is Dependent on Modulation of Specific Cell Cycle Regulators by Thyroid Hormone Endocrinology, January 1, 2006; 147(1): 272 - 282. [Abstract] [Full Text] [PDF]

				K. S. Dhillon, P. Cohan, D. F. Kelly, C. H. Darwin, K. V. Iyer, and I. J. Chopra Treatment of Hyperthyroidism Associated with Thyrotropin-Secreting Pituitary Adenomas with Iopanoic Acid J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 708 - 711. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				W. W. Woodmansee, R. L. Mouser, D. F. Gordon, J. M. Dowding, W. M. Wood, and E. C. Ridgway Mutational Analysis of the Mouse Somatostatin Receptor Type 5 Gene Promoter Endocrinology, June 1, 2002; 143(6): 2268 - 2276. [Abstract] [Full Text] [PDF]

				P. Caron, S. Arlot, C. Bauters, P. Chanson, J.-M. Kuhn, M. Pugeat, R. Marechaud, C. Teutsch, E. Vidal, and P. Sassano Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2849 - 2853. [Abstract] [Full Text] [PDF]

				J. M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, P. Chanson, A. Tabarin, M. Goth, J. Blumberg, et al. Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1487 - 1491. [Abstract] [Full Text]

				Pituitary Tumors in Children and Adolescents J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4317 - 4323. [Full Text]

				F. Brucker-Davis, E. H. Oldfield, M. C. Skarulis, J. L. Doppman, and B. D. Weintraub Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 476 - 486. [Abstract] [Full Text]

				N N Chan and A J Isaacs Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma Postgrad. Med. J., February 1, 1999; 75(880): 96 - 98. [Abstract] [Full Text]

				P. Caron, L. Buscail, A. Beckers, J.-P. Esteve, A. Igout, G. Hennen, and C. Susini Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during Pregnancy J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3771 - 3776. [Abstract] [Full Text] [PDF]

				S. W.J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Hofland Octreotide N. Engl. J. Med., January 25, 1996; 334(4): 246 - 254. [Full Text] [PDF]

				P. Caron, C. Gerbeau, and L. Pradayrol Maternal-Fetal Transfer of Octreotide N. Engl. J. Med., August 31, 1995; 333(9): 601 - 602. [Full Text]